Since OTC deficiency is a rare X-linked genetic disorder, companies in the ornithine transcarbamylase (OTC) deficiency treatment market are under pressure to increase the availability of drugs amidst the COVID-19 (coronavirus) outbreak. Messenger RNA drug developer Arcturus Therapeutics has not only received the FDA’s (Food & Drug Association) approval for clinical trials of ARCT-810, an investigational treatment for OTC deficiency, but is also testing its coronavirus vaccine candidate. Thus, companies in the ornithine transcarbamylase (OTC) deficiency treatment market are tapping revenue opportunities by innovating in COVID-19 vaccines.
OTC deficiency is a life-threatening disorder, which needs extra care and attention during the COVID-19 pandemic. Companies are collaborating with retail and hospital pharmacies to avoid supply shocks for OTC deficiency medications, as most individuals are opting for remote healthcare diagnosis. They are innovating in intravenous (IV) medications since no FDA-approved drugs exist for the disorder.
Request a sample to get extensive insights into the Ornithine Transcarbamylase (OTC) Deficiency Treatment Market
Gene therapy holds promising potentials in ornithine transcarbamylase (OTC) deficiency treatment. The Boston Children’s Hospital is creating awareness about gene therapy, since OTC deficiency is a genetic condition caused due to the mutation of the OTC gene. By providing a healthy copy of the OTC gene through gene therapy, doctors aim to reduce incidence of neurological deficits and liver damage. Liver transplantation is another solution for ornithine transcarbamylase deficiency treatment.
Companies in the ornithine transcarbamylase (OTC) deficiency treatment market are increasing their production capabilities to manufacture BUPHENYL® (sodium phenylbutyrate) tablets and powder for oral administration. Since urea cycle disorders are commonly associated with the OTC deficiency, manufacturers in the ornithine transcarbamylase (OTC) deficiency treatment market are increasing the availability of BUPHENYL® to minimize adverse events in patients. BUPHENYL® is being used as an adjunctive therapy for chronic management of OTC deficiency.
To understand how our report can bring difference to your business strategy, Ask for a brochure
Ravicti has become the gold standard for the treatment of the OTC deficiency. This oral liquid is being increasingly used for long-term management of high blood levels containing ammonia that commonly lead to urea cycle disorders (UCDs). Healthcare practitioners are recommending low-protein diet and dietary supplements to OTC deficiency patients. However, Ravicti has limitations for the treatment of extremely high levels of ammonia in the blood, especially in patients with UCD. This explains why the market is estimated to register a modest CAGR of ~4% during the forecast period. Hence, companies in the ornithine transcarbamylase (OTC) deficiency treatment market are increasing awareness about the safety of Ravicti to avoid serious side effects in patients.
OTC deficiency patients with kidney and liver problems need to seek doctor’s consultation before consuming Ravicti. Clinicians are providing special care to pregnant women and women who are breastfeeding to avoid any adverse events in infants.
Stuck in a neck-to-neck competition with other brands? Request a custom report on Ornithine Transcarbamylase (OTC) Deficiency Treatment Market
The FDA prescribed information is being used by medical practitioners to administer the doses of Ammonul in OTC deficiency patients. Genetics and metabolic experts are recommending hemodialysis as an effective solution to reduce plasma ammonia in OTC deficiency patients. As such, Ammonul is being extensively taken via intravenous administration to reduce the severity of UCDs. Ammonul IV helps in removing glycine and glutamate from plasma, thereby reducing contribution to ammonia formation. Thus, companies in the ornithine transcarbamylase (OTC) deficiency treatment market are increasing their R&D capabilities to develop improved formulations of Ammonul IV.
Since the management and diagnosis of UCD is complex, pathologists, nephrologists, and geneticists are stepping in to lower ammonia levels in the blood of OTC deficiency patients.
The ornithine transcarbamylase (OTC) deficiency treatment market is projected to reach ~US$ 900 Mn by the end of 2030. However, limited consensus regarding long-term management approaches for OTC deficiency is potentially inhibiting market growth. Hence, pharmaceutical companies are introducing efficacious dietary supplements to keep ammonia levels in the blood under control. On the other hand, nitrogen scavenger therapy is being highly publicized to ensure long-term UCD management and to minimize the nitrogen load.
Companies in the ornithine transcarbamylase (OTC) deficiency treatment market are increasing awareness about a multidisciplinary approach for long-term UCD management. Since the male population is at a higher risk of being susceptible to the OTC deficiency, biochemical geneticists, dieticians and neuropsychologists are collaborating to introduce guidelines associated with chronic ammonia targets.
It has been found that a dietician’s consultation helps to improve clinical outcomes in OTC deficiency patients. Along with dietary supplements, nutritionists are recommending low-protein diets to improve the quality of life for OTC deficiency individuals. Patients that are adherent to the UCD therapy are also warranted for genetic testing to ensure successful management of OTC deficiency. Dieticians are playing an instrumental role in complex calculations related to the intake of protein and dietary supplements, which depends on different variables such as age-related growth rate, physical activity, and residual urea cycle function.
Providing the right amount of protein is necessary for efficient management of the OTC deficiency. Hence, companies in the ornithine transcarbamylase (OTC) deficiency treatment market are suggesting routine diagnosis of the rare disorder in order to increase clinical numbers. IV and oral drugs are being routinely used for long-term management of UCD in OTC deficiency patients.
Analysts’ Viewpoint
Since UCD associated with OTC deficiency can be potentially life threating for patients amidst the COVID-19 pandemic, companies in the ornithine transcarbamylase (OTC) deficiency treatment market are boosting their production capacities to increase the availability of IV and oral drugs. Gene therapy and nitrogen scavenger therapy are gaining popularity for long-term management of ammonia in blood streams. Since there is a lack of FDA-approved drugs for the OTC deficiency, companies in the ornithine transcarbamylase (OTC) deficiency treatment market should increase their R&D capabilities to innovate in IV medications. Companies should innovate in dietary supplements, since a close check on daily intake of protein and supplements helps to improve patient quality of life.
Ornithine Transcarbamylase (OTC) Deficiency Treatment Market – Segmentation
TMR’s study on the global ornithine transcarbamylase (OTC) deficiency treatment market includes information divided into four sections: product, route of administration, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these sections of the global ornithine transcarbamylase (OTC) deficiency treatment market have been discussed in detail.
|
Product |
|
|
Route of Administration |
|
|
Distribution Channel |
|
|
Region |
|
Ornithine transcarbamylase (OTC) deficiency treatment market is projected to reach ~US$ 900 Mn by 2030
Ornithine transcarbamylase (OTC) deficiency treatment market is projected to expand at a CAGR of ~4% from 2020 to 2030
Ornithine transcarbamylase (OTC) deficiency treatment market is driven by rising prevalence of OTC deficiency and development of new therapies for the treatment of OTC deficiency
North America accounted for a major share of the global ornithine transcarbamylase (OTC) deficiency treatment market
Key players in the global ornithine transcarbamylase (OTC) deficiency treatment market include Abbott, Nutricia (Danone Group), Mead Johnson (Reckitt Benckiser), Horizon Therapeutics plc, Nestlé, Bausch Health Companies
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, 2018–2030
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Disease Prevalence & Incidence Rate globally with key countries
5.2. Pipeline Analysis
5.3. Standard Guidelines for Approval of Drugs
5.4. Overview of Diagnostics approach for OTC Deficiency
5.5. COVID-19 Pandemics Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
6. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030
6.3.1. Buphenyl
6.3.2. Ravicti
6.3.3. Ammonul
6.3.4. Dietary Supplements
6.3.5. Others
6.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Product
7. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030
7.3.1. Oral
7.3.2. Intravenous
7.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Route of Administration
8. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Distribution Channel
9. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Country/Region
10. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030
10.2.1. Buphenyl
10.2.2. Ravicti
10.2.3. Ammonul
10.2.4. Dietary Supplements
10.2.5. Others
10.3. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030
10.3.1. Oral
10.3.2. Intravenous
10.4. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country, 2018–2030
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030
11.2.1. Buphenyl
11.2.2. Ravicti
11.2.3. Ammonul
11.2.4. Dietary Supplements
11.2.5. Others
11.3. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030
11.3.1. Oral
11.3.2. Intravenous
11.4. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030
12.2.1. Buphenyl
12.2.2. Ravicti
12.2.3. Ammonul
12.2.4. Dietary Supplements
12.2.5. Others
12.3. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030
12.3.1. Oral
12.3.2. Intravenous
12.4. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030
13.2.1. Buphenyl
13.2.2. Ravicti
13.2.3. Ammonul
13.2.4. Dietary Supplements
13.2.5. Others
13.3. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030
13.3.1. Oral
13.3.2. Intravenous
13.4. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030
14.2.1. Buphenyl
14.2.2. Ravicti
14.2.3. Ammonul
14.2.4. Dietary Supplements
14.2.5. Others
14.3. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030
14.3.1. Oral
14.3.2. Intravenous
14.4. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share/Position Analysis, by Company (2019)
15.3. Company Profiles
15.3.1. Abbott
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Company Financials
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. Nutricia (Danone Group)
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Company Financials
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. Mead Johnson (Reckitt Benckiser)
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Company Financials
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. Horizon Therapeutics plc
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Company Financials
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. Nestlé
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Company Financials
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. Bausch Health Companies, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Company Financials
15.3.6.3. Growth Strategies
15.3.6.4. SWOT Analysis
15.3.7. Ultragenyx Pharmaceutical Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Company Financials
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. Arcturus Therapeutics, Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Company Financials
15.3.8.3. Growth Strategies
15.3.8.4. SWOT Analysis
15.3.9. Acer Therapeutics
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Company Financials
15.3.9.3. Growth Strategies
15.3.9.4. SWOT Analysis
List of Tables
Table 01: Pipeline Analysis
Table 02: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030
Table 03: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 04: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 05: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 06: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 07: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030
Table 08: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 09: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 10: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 11: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030
Table 12: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 13: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 14: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 15: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030
Table 16: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 17: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 18: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 19: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030
Table 20: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 21: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 22: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 23: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030
Table 24: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 25: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
List of Figures
Figure 01: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, 2018–2030
Figure 02: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share, by Product, 2019
Figure 03: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share, by Route of Administration, 2019
Figure 04: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share, by Distribution Channel, 2019
Figure 05: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share, by Region, 2019
Figure 06: Regulatory Approval Process - U.S.
Figure 07: Regulatory Approval Process - Europe
Figure 08: Regulatory Approval Process - Japan
Figure 09: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share Analysis, by Product, 2019 and 2030
Figure 10: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Buphenyl, 2018–2030
Figure 11: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Ravicti, 2018–2030
Figure 12: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Ammonul, 2018–2030
Figure 13: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Dietary Supplements, 2018–2030
Figure 14: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Others, 2018–2030
Figure 15: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis, by Product, 2020–2030
Figure 16: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 17: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Oral, 2018–2030
Figure 18: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Intravenous, 2018–2030
Figure 19: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 20: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 21: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2018-2030
Figure 22: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2018-2030
Figure 23: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Online Pharmacies, 2018–2030
Figure 24: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 25: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share Analysis, by Region, 2019 and 2030
Figure 26: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis, by Region, 2020–2030
Figure 27: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 28: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Country, 2019 and 2030
Figure 29: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Country, 2020–2030
Figure 30: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Product, 2019 and 2030
Figure 31: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Product, 2020–2030
Figure 32: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 33: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Route of Administration, 2020–2030
Figure 34: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 35: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Distribution Channel, 2020–2030
Figure 36: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 37: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 38: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Country/Sub-region, 2020–2030
Figure 39: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Product, 2019 and 2030
Figure 40: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Product, 2020–2030
Figure 41: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 42: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Route of Administration, 2020–2030
Figure 43: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 44: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Distribution Channel, 2020–2030
Figure 45: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 46: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 47: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Country/Sub-region, 2020–2030
Figure 48: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Product, 2019 and 2030
Figure 49: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Product, 2020–2030
Figure 50: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 51: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Route of Administration, 2020–2030
Figure 52: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 53: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Distribution Channel, 2020–2030
Figure 54: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 55: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 56: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Country/Sub-region, 2020–2030
Figure 57: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Product, 2019 and 2030
Figure 58: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Product, 2020–2030
Figure 59: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 60: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Route of Administration, 2020–2030
Figure 61: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 62: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Distribution Channel, 2020–2030
Figure 63: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 64: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 65: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Country/Sub-region, 2020–2030
Figure 66: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Product, 2019 and 2030
Figure 67: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Product, 2020–2030
Figure 68: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 69: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Route of Administration, 2020–2030
Figure 70: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 71: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Distribution Channel, 2020–2030
Figure 72: Market Position Analysis, 2019, by Tier and Size of Company
Figure 73: Abbott, Nutritional Business Segment - Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2019
Figure 74: Abbott, Nutritional Business Segment - Breakdown of Net Sales (%), by Region/Country, 2019
Figure 75: Abbott, Breakdown of Net Sales (%), by Nutritional Business Segment, 2019
Figure 76: Abbott, R&D Expenses (US$ Mn) Y-o-Y Growth (%), 2016–2019
Figure 77: Danone - Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2019
Figure 78: Danone - Breakdown of Net Sales (%), by Region/Country, 2019
Figure 79: Danone - Breakdown of Net Sales (%), by Business Segment, 2019
Figure 80: Reckitt Benckiser - Revenue (US$ Mn), 2016–2018
Figure 81: Reckitt Benckiser - Breakdown of Net Sales (%), by Region/Country, 2018
Figure 82: Reckitt Benckiser - Breakdown of Net Sales (%), by Business Segment, 2018
Figure 83: Horizon Therapeutics plc - Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2019
Figure 84: Horizon Therapeutics plc - Breakdown of Net Sales (%), by Region/County, 2019
Figure 85: Horizon Therapeutics plc - Breakdown of Net Sales (%), by Business Segment, 2019
Figure 86: RAVICTI & BUPHENYL - Product Revenue (US$ Mn), 2017–2019
Figure 87: Nestlé - Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019
Figure 88: Nestlé - Breakdown of Net Sales (%), by Region/County, 2019
Figure 89: Nestlé - Breakdown of Net Sales (%), by Product Line, 2019
Figure 90: Bausch Health Companies, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019
Figure 91: Bausch Health Companies, Inc., Breakdown of Net Sales (%), by Region/County, 2019
Figure 92: Bausch Health Companies, Inc., Breakdown of Net Sales (%), by Business Segment, 2019
Figure 93: Bausch Health Companies, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2019
Figure 94: Ultragenyx Pharmaceutical, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2019
Figure 95: Ultragenyx Pharmaceutical, Inc., Breakdown of Net Sales (%), by Region/County, 2019
Figure 96: Ultragenyx Pharmaceutical, Inc., DTX301 - R&D Expenses (US$ Mn) Y-o-Y Growth (%), 2018–2019
Figure 97: Ultragenyx Pharmaceutical, Inc., R&D Expenses (US$ Mn) Y-o-Y Growth (%), 2016–2019
Figure 98: Arcturus Therapeutics, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019
Figure 99: Arcturus Therapeutics, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2019
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Ornithine Transcarbamylase (OTC) Deficiency Treatment Market
*86 figures and 60 tables includes